Telisotuzumab Vedotin-Tllv Market

Telisotuzumab Vedotin-Tllv API market is experiencing a CAGR of 9.7% during the forecast period from 2025 to 2035. The market growth is driven by the increasing demand for targeted cancer therapies, particularly in non-small cell lung cancer (NSCLC). As an investigational antibody-drug conjugate (ADC) targeting c-Met overexpression, telisotuzumab vedotin represents a promising treatment option in precision oncology.

The key segment of this market is clinical-grade APIs used in Phase II and III trials, followed by pre-commercial batch production for regulatory submissions. Given the complexity of ADC manufacturing, there is a growing reliance on contract development and manufacturing organizations (CDMOs) that can support both biologic antibody production and cytotoxic payload conjugation.

North America, particularly the US, dominates the Telisotuzumab Vedotin-tllv API market due to high R&D spending, the presence of AbbVie (the originator), and a strong pipeline of ADC clinical trials. The Asia-Pacific region, especially China and South Korea, is additionally emerging as a key contributor due to cost-effective manufacturing capabilities and increasing focus on biologics and oncology drug development.

Recent Developments

• In May 2025, the US FDA approved EMRELIS (telisotuzumab vedotin-tllv) for adults with advanced non-small cell lung cancer (NSCLC) with high c-Met protein overexpression. The treatment is based on the overall response rate and duration of response. EMRELIS is a c-Met-directed antibody-drug conjugate (ADC) and the first approved for this patient population. NSCLC is the leading cause of cancer-related deaths worldwide, with 85% of lung cancers classified as NSCLC. Approximately half of these patients have high c-Met overexpression.
• In May 2025, the FDA approved telisotuzumab vedotin-tllv, a c-Met-directed antibody, and microtubule inhibitor conjugate, for adults with advanced or metastatic NSCLC with high c-Met protein overexpression. The FDA also approved the VENTANA MET RxDx Assay for detecting c-Met protein overexpression.